市場調査レポート

世界の院内感染性肺炎市場におけるパイプライン分析(リン酸テジゾリド、Ceftolozane/Tazobactam、Ceftazidime/Avibactam、吸入型アミカシン、Plazomicin、Synflorixワクチン)- 産業分析・市場規模・シェア・成長・動向・予測

Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

発行 Transparency Market Research 商品コード 312133
出版日 ページ情報 英文 74 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
世界の院内感染性肺炎市場におけるパイプライン分析(リン酸テジゾリド、Ceftolozane/Tazobactam、Ceftazidime/Avibactam、吸入型アミカシン、Plazomicin、Synflorixワクチン)- 産業分析・市場規模・シェア・成長・動向・予測 Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
出版日: 2014年09月01日 ページ情報: 英文 74 Pages
概要

院内感染性肺炎は、医療関連肺炎または院内肺炎とも呼ばれ、病院の敷地内において罹患します。地域感染型の肺炎とは違い、院内感染性肺炎は主として多剤耐性微生物によって引き起こされます。世界の院内感染性肺炎薬剤市場は、世界的な院内肺炎有病率の増加によってその成長が促されます。

当レポートでは、世界の院内感染性肺炎市場の現状と見通し、院内肺炎治療のための後期候補薬および臨床試験の初期段階にある薬剤を詳細に調査し、市場成長促進要因・阻害要因および市場機会の分析、主要な6種の後期(第III相)薬剤および10種の初期(第I相、第II相)候補薬の調査および見通し、ならびに主要企業のプロファイルをまとめています。

第1章 イントロダクション

  • 調査の説明
  • 市場区分
  • 調査手法
  • 略語
  • 前提

第2章 エグゼクティブサマリー

  • 院内感染性肺炎第III相候補薬、市場シェア、2020年(金額ベース%)

第3章 市場概要

  • イントロダクション
    • 院内肺炎の種類
      • 細菌性肺炎
      • ウイルス性肺炎
    • 院内感染性肺炎の疫学
    • 院内感染性肺炎の診断
    • 院内感染性肺炎の治療
  • 市場動態
    • 市場成長促進要因
      • 感染性細菌の薬物耐性の強化が院内感染性肺炎の機会を増やしている
      • 低・中所得国における非効率的な消毒と非衛生的な条件が院内感染性肺炎の有病率を増大
    • 市場成長阻害要因
      • 政府が院内感染性肺炎抑制のため入院費用保険を詳細に調査
    • 市場機会
      • 院内肺炎市場におけるワクチンの有望な将来
      • 肺炎球菌以外の原因物質に対するワクチン開発の研究における可能性
  • イベント影響分析
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • 院内感染性肺炎向け主要薬物およびワクチンの市場分析
    • 院内肺炎市場における主要ブランド薬物およびワクチンの売上動向(百万米ドル)

第4章 院内感染性肺炎、パイプライン分析

  • イントロダクション
  • 後期(第III相)
    • リン酸テジゾリド
    • Ceftolozane/Tazobactam
    • Ceftazidime/Avibactam
    • 吸入型アミカシン
    • Plazomicin
    • Synflorixワクチン
  • 初期(第I相、第II相)
    • BAL30072
    • MEDI4893
    • AR-301またはKBSA301
    • AR-101(またはKBPA101)とAR-104(またはKBPA104)
    • AR-201(またはKBRV201)
    • AR-401(またはKBAB401)
    • ME1100
    • GSK 2189242A
    • V114
    • IC43

第5章 世界の院内感染性肺炎市場におけるパイプラインのレビュー、地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • その他地域

第6章 提言

  • 生物学的製剤の研究開発
  • 合併、買収、戦略敵合意

第7章 企業プロファイル(企業概要、業績概要、製品ポートフォリオ、事業戦略、最近の動き)

  • Achaogen, Inc.
  • Aridis Pharmaceuticals
  • AstraZeneca plc
  • Cubist Pharmaceuticals, Inc.
  • Meiji Seika ファルマ
  • Merck & Co. Inc.
  • Sanofi
  • GlaxoSmithKline, Inc.
  • Valneva SE
目次

Hospital-acquired pneumonia also called as healthcare associated pneumonia or nosocomial pneumonia is acquired in hospital premises. Unlike community acquired pneumonia hospital acquired pneumonia is mainly caused due to multidrug resistant microorganisms. The report analyzes the market for late stage candidates for treatment of nosocomial pneumonia, and also provides a detailed review of drugs in early stages of clinical trials. The report studies and estimates market for six late stage along with an elucidation of ten early stage candidates for nosocomial pneumonia treatment.

Phase III candidates include tedizolid phosphate, ceftolozane/tazobactam, ceftazidime/avibactam, amikacin inhale, plazomicin and synflorix vaccine. Market for each of the investigational drugs is estimated based on current anti-microbial efficiency, historic market trend and patents of drugs from similar class, manufacturing and marketing licenses, along with competition from commercialized and pipeline drugs. Hospital acquired pneumonia drugs market for phase III candidates has been estimated from the expected year of launch till 2020. The hospital acquired pneumonia drugs market report also gives a brief review of the various drugs commercially available for treating hospital acquired pneumonia. Historic market revenue of these drugs from 2011 to 2013 has also been included. Market forecast mainly rests on a detailed event impact analysis, which considers historic as well as anticipated events which impact the market in varying degrees.

Global market for hospital acquired pneumonia drugs is mainly driven by the increasing prevalence of nosocomial infections across the globe. To illustrate this fact, the report includes a statistical comparison of the prevalence of nosocomial infections in various developed and developing countries. Geographical trend of hospital acquired pneumonia drugs market, is explains with a brief regulatory approval process, along with expected time frame for drug launch in various countries. These trends have been explained for geographical regions including North America, Europe, Asia Pacific and Rest of the World.

To gain a complete market understanding, Porters Five Force's analysis, and value chain analysis has also been included in the hospital acquired pneumonia drugs market report. The report also explains key market drivers, restraints, opportunities in the hospital acquired pneumonia drugs market. Diagnosis, treatment, and epidemiology of hospital acquired pneumonia gives a clinical overview of the disease and current modes of disease management. Relevant recommendations have been suggested for designing successful market strategies for competing in the market.

Hospital acquired pneumonia drugs market report also includes company profiles of key market players. These include Achaogen, Inc., Aridis Pharmaceuticals, AstraZeneca plc, Cubist Pharmaceuticals, Inc., Meiji Seika Pharma Co. Ltd., Merck & Co. Ltd., Sanofi, GlaxoSmithKline, Inc., and Valneva SE. All of these players are profiled considering company overview, financial overview, product portfolio, business strategies, and recent developments.

The research methodology was based on primary as well as secondary research. Interviews and discussions with a wide range of key industry participants and opinion leaders revealed real time market scenario. This primary research represented the bulk of the research efforts, which was further supplemented by extensive secondary research. A review of key players' product literature, annual reports, and press releases supports the market forecast analysis. The 74 page report explains various market dynamics in 4 tables and 17 figures and charts.

Table of Contents

Chapter 1 Introduction

  • 1.1 Report Description
  • 1.2 Market Segmentation
  • 1.3 Research Methodology
    • 1.3.1 Secondary Research
    • 1.3.2 Primary Research
  • 1.4 List of Abbreviations
  • 1.5 Assumptions

Chapter 2 Executive Summary

  • 2.1.1 Hospital Acquired Pneumonia Phase III Candidates, Market Share, 2020 (Value %)

Chapter 3 Market overview

  • 3.1 Introduction
    • 3.1.1 Types of Nosocomial Pneumonia
      • 3.1.1.1 Bacterial pneumonia
      • 3.1.1.2 Viral pneumonia
    • 3.1.2 Epidemiology of hospital acquired pneumonia
    • 3.1.3 Diagnosis of hospital acquired pneumonia
    • 3.1.4 Treatment of hospital acquired pneumonia
  • 3.2 Market Dynamics
    • 3.2.1 Market Drivers
      • 3.2.1.1 Rising drug resistance among infectious microorganisms increasing chances of hospital acquired infections
      • 3.2.1.2 Inefficient sterilization and unhygienic conditions in low and middle income countries increasing prevalence of hospital acquired infections
        • 3.2.1.2.1 Prevalence of hospital acquired infections in developed and developing countries
    • 3.2.2 Market Restraints
      • 3.2.2.1 Government scrutinizing hospital policies to curb hospital-acquired infections
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Promising future for vaccines in the nosocomial pneumonia market
      • 3.2.3.2 Potential for research in vaccine development for causative agents other than S. pneumonia
  • 3.3 Event Impact Analysis
    • 3.3.1 Event Impact Analysis: Hospital Acquired Pneumonia Market
  • 3.4 Value Chain Analysis
    • 3.4.1 Value Chain Analysis
  • 3.5 Porter's Five Forces Analysis for the Global Hospital Acquired Pneumonia Drugs Market
    • 3.5.1 Bargaining Power of Suppliers
    • 3.5.2 Porter's Five Forces Analysis: Global Hospital Acquired Pneumonia Market
    • 3.5.3 Bargaining Power of Buyers
    • 3.5.4 Threat of Substitutes
    • 3.5.5 Threat of New Entrants
    • 3.5.6 Competitive Rivalry
  • 3.6 Market Analysis of Major Drugs and Vaccines for Hospital Acquired Pneumonia
    • 3.6.1 Revenue trend of major branded drugs and vaccines in nosocomial pneumonia market (USD Million)

Chapter 4 Hospital Acquired Pneumonia, Pipeline Analysis

  • 4.1 Introduction
  • 4.2 Late Stage (Phase III)
    • 4.2.1 Tedizolid phosphate
      • 4.2.1.1 Global Tedizolid Phosphate Market Revenue, 2017 - 2020 (USD million)
    • 4.2.2 Ceftolozane/Tazobactam
      • 4.2.2.1 Global Ceftolozane/Tazobactam Market Revenue, 2017 - 2020 (USD million)
    • 4.2.3 Ceftazidime/Avibactum
      • 4.2.3.1 Global Ceftazidime/Avibactam Market Revenue, 2017 - 2020 (USD Million)
    • 4.2.4 Amikacin Inhale
      • 4.2.4.1 Global Amikacin Inhale Market Revenue, 2016 - 2020 (USD Million)
    • 4.2.5 Plazomicin
      • 4.2.5.1 Global Plazomicin Market Revenue, 2017 - 2020 (USD Million)
    • 4.2.6 Synflorix Vaccine
      • 4.2.6.1 Global Synflorix Market Revenue, 2012 - 2020 (USD Million)
  • 4.3 Early Stage (Phase I and II)
    • 4.3.1 BAL30072
    • 4.3.2 MEDI4893
    • 4.3.3 AR-301 or KBSA301
    • 4.3.4 AR-101 (or KBPA101) and AR-104 (or KBPA104)
    • 4.3.5 AR-201 (or KBRV201)
    • 4.3.6 AR-401 (or KBAB401)
    • 4.3.7 ME1100
    • 4.3.8 GSK 2189242A
    • 4.3.9 V114
    • 4.3.10 IC43

Chapter 5 Global Pipeline Review of Hospital Acquired Pneumonia Drugs Market, by Geography

  • 5.1 Introduction
  • 5.2 North America
  • 5.3 Europe
  • 5.4 Asia Pacific
  • 5.5 Rest of the World

Chapter 6 Recommendations

  • 6.1 Research and development for biological drugs
  • 6.2 Mergers, acquisitions and strategic agreements

Chapter 7 Company Profiles

  • 7.1 Achaogen, Inc.
    • 7.1.1 Company Overview
    • 7.1.2 Financial Overview
    • 7.1.3 Product Portfolio
    • 7.1.4 Business Strategies
    • 7.1.5 Recent Developments
  • 7.2 Aridis Pharmaceuticals
    • 7.2.1 Company Overview
    • 7.2.2 Financial Overview
    • 7.2.3 Product Portfolio
    • 7.2.4 Business Strategies
    • 7.2.5 Recent Developments
  • 7.3 AstraZeneca plc
    • 7.3.1 Company Profile
    • 7.3.2 Financial Overview
    • 7.3.3 Product Portfolio
    • 7.3.4 Business Strategies
    • 7.3.5 Recent Developments
  • 7.4 Cubist Pharmaceuticals, Inc.
    • 7.4.1 Company Overview
    • 7.4.2 Financial Overview
    • 7.4.3 Product Portfolio
    • 7.4.4 Business Strategies
  • 7.5 Meiji Seika Pharma Co. Ltd.
    • 7.5.1 Company Overview
    • 7.5.2 Financial Overview
    • 7.5.3 Product Portfolio
    • 7.5.4 Business Strategies
    • 7.5.5 Recent Developments
  • 7.6 Merck & Co. Inc.
    • 7.6.1 Company Overview
    • 7.6.2 Financial Overview
    • 7.6.3 Product Portfolio
    • 7.6.4 Business Strategies
    • 7.6.5 Recent Developments
  • 7.7 Sanofi
    • 7.7.1 Company Overview
    • 7.7.2 Financial Overview
    • 7.7.3 Product Portfolio
    • 7.7.4 Business Strategies
    • 7.7.5 Recent Developments
  • 7.8 GlaxoSmithKline, Inc.
    • 7.8.1 Company Overview
    • 7.8.2 Financial Overview
    • 7.8.3 Product Portfolio
    • 7.8.4 Business Strategies
    • 7.8.5 Recent Developments
  • 7.9 Valneva SE
    • 7.9.1 Company Overview
    • 7.9.2 Financial Overview
    • 7.9.3 Product Portfolio
    • 7.9.4 Business Strategies
    • 7.9.5 Recent Developments

List of Figures

  • FIG. 1 Hospital Acquired Pneumonia: Drug Pipeline
  • FIG. 2 Hospital Acquired Pneumonia Phase III Candidates, Market Share, 2020 (Value %)
  • FIG. 3 Value Chain Analysis
  • FIG. 4 Porter's Five Forces Analysis: Global Hospital Acquired Pneumonia Market
  • FIG. 5 Revenue trend of major branded drugs and vaccines in nosocomial pneumonia market (USD Million)
  • FIG. 6 Global Tedizolid Phosphate Market Revenue, 2017 - 2020 (USD Million)
  • FIG. 7 Global Ceftolozane/Tazobactam Market Revenue, 2017 - 2020 (USD million)
  • FIG. 8 Global Ceftazidime/Avibactam Market Revenue, 2017 - 2020 (USD Million)
  • FIG. 9 Global Amikacin Inhale Market Revenue, 2016 - 2020 (USD Million)
  • FIG. 10 Global Plazomicin Market Revenue, 2017 - 2020 (USD Million)
  • FIG. 11 Global Synflorix Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 12 AstraZeneca PLC: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 13 Cubist Pharmaceuticals, Inc.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 14 Meiji Holdings, Co. Ltd., Pharmaceutical Segment.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 15 Merck & Co. Inc.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 16 Sanofi: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 17 GlaxoSmithKline, Inc.: Annual Revenue, 2011 - 2013 (USD Million)

List of Tables

  • TABLE 1 Nosocomial Pneumonia Drugs and Vaccines, Market Snapshot
  • TABLE 2 Investigational Candidates for Nosocomial Pneumonia Treatment
  • TABLE 3 Prevalence of Hospital Acquired Infections in Developed and Developing Countries
  • TABLE 4 Event Impact Analysis, Hospital Acquired Pneumonia Market
Back to Top